Kahn Brothers Group Inc. DE decreased its position in shares of Bristol-Myers Squibb Company (NYSE:BMY) by 31.5% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 19,583 shares of the biopharmaceutical company’s stock after selling 9,000 shares during the quarter. Bristol-Myers Squibb makes up 0.2% of Kahn Brothers Group Inc. DE’s holdings, making the stock its 25th largest holding. Kahn Brothers Group Inc. DE’s holdings in Bristol-Myers Squibb were worth $1,091,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of BMY. Wealth Architects LLC grew its position in shares of Bristol-Myers Squibb by 0.8% during the 1st quarter. Wealth Architects LLC now owns 6,993 shares of the biopharmaceutical company’s stock worth $380,000 after buying an additional 56 shares in the last quarter. Empire Life Investments Inc. lifted its stake in shares of Bristol-Myers Squibb by 16.3% during the 1st quarter. Empire Life Investments Inc. now owns 60,551 shares of the biopharmaceutical company’s stock worth $3,292,000 after purchasing an additional 8,499 shares during the last quarter. WealthTrust Fairport LLC lifted its stake in shares of Bristol-Myers Squibb by 48.8% during the 1st quarter. WealthTrust Fairport LLC now owns 6,333 shares of the biopharmaceutical company’s stock worth $344,000 after purchasing an additional 2,076 shares during the last quarter. Rhumbline Advisers lifted its stake in shares of Bristol-Myers Squibb by 1.3% during the 1st quarter. Rhumbline Advisers now owns 2,549,646 shares of the biopharmaceutical company’s stock worth $138,650,000 after purchasing an additional 33,766 shares during the last quarter. Finally, First Trust Advisors LP lifted its stake in shares of Bristol-Myers Squibb by 54.5% during the 1st quarter. First Trust Advisors LP now owns 391,158 shares of the biopharmaceutical company’s stock worth $21,271,000 after purchasing an additional 137,941 shares during the last quarter. 69.14% of the stock is currently owned by institutional investors and hedge funds.

A number of brokerages recently weighed in on BMY. Vetr cut Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating and set a $64.20 price objective for the company. in a research note on Tuesday, August 22nd. Citigroup Inc. set a $72.00 price objective on Bristol-Myers Squibb and gave the stock a “buy” rating in a research note on Wednesday, October 25th. BMO Capital Markets set a $49.00 price objective on Bristol-Myers Squibb and gave the stock a “sell” rating in a research note on Thursday, October 26th. Deutsche Bank AG set a $55.00 price objective on Bristol-Myers Squibb and gave the stock a “hold” rating in a research note on Monday, July 17th. Finally, Credit Suisse Group set a $58.00 price objective on Bristol-Myers Squibb and gave the stock a “hold” rating in a research note on Wednesday, August 16th. One investment analyst has rated the stock with a sell rating, ten have assigned a hold rating and eleven have assigned a buy rating to the company’s stock. Bristol-Myers Squibb currently has an average rating of “Hold” and a consensus price target of $64.93.

TRADEMARK VIOLATION NOTICE: This story was first published by Watch List News and is the property of of Watch List News. If you are accessing this story on another publication, it was stolen and reposted in violation of international copyright & trademark laws. The correct version of this story can be viewed at https://www.watchlistnews.com/kahn-brothers-group-inc-de-sells-9000-shares-of-bristol-myers-squibb-company-bmy/1697226.html.

In other news, SVP Joseph C. Caldarella sold 9,340 shares of Bristol-Myers Squibb stock in a transaction on Wednesday, September 6th. The stock was sold at an average price of $60.00, for a total value of $560,400.00. Following the completion of the sale, the senior vice president now directly owns 46,297 shares of the company’s stock, valued at $2,777,820. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Insiders own 0.23% of the company’s stock.

Bristol-Myers Squibb Company (NYSE:BMY) opened at $60.86 on Friday. Bristol-Myers Squibb Company has a 1 year low of $46.01 and a 1 year high of $66.10. The company has a market capitalization of $99,609.56, a P/E ratio of 20.56, a P/E/G ratio of 2.40 and a beta of 1.18. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.46 and a current ratio of 1.59.

Bristol-Myers Squibb (NYSE:BMY) last posted its earnings results on Thursday, October 26th. The biopharmaceutical company reported $0.75 EPS for the quarter, missing the Zacks’ consensus estimate of $0.77 by ($0.02). Bristol-Myers Squibb had a net margin of 20.56% and a return on equity of 32.41%. The business had revenue of $5.25 billion during the quarter, compared to analysts’ expectations of $5.20 billion. During the same quarter in the prior year, the firm earned $0.77 EPS. Bristol-Myers Squibb’s revenue for the quarter was up 6.7% compared to the same quarter last year. analysts forecast that Bristol-Myers Squibb Company will post 2.99 EPS for the current year.

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, November 1st. Stockholders of record on Friday, October 6th were paid a $0.39 dividend. The ex-dividend date was Thursday, October 5th. This represents a $1.56 dividend on an annualized basis and a dividend yield of 2.56%. Bristol-Myers Squibb’s payout ratio is presently 61.42%.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Company and related companies with Analyst Ratings Network's FREE daily email newsletter.